Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros










Intervalo de año de publicación
1.
BMJ Open Ophthalmol ; 8(Suppl 2): A19, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37604545

RESUMEN

Endothelial bioengineering is the simplest form of corneal bioengineering insofar as it consists of producing a large quantity of corneal endothelial cells and packaging them in a form that can be transplanted to the patient. It seems to be the most realistic solution to replace endothelial grafts made from donor corneas and thus allow, by domino effect, to reserve them for other indications of keratoplasty. Kyoto ophthalmologists (S Kinoshita, N Koizumi and N Okumura) were the pioneers of injection therapy by demonstrating its feasibility and safety, with an efficacy at 5 years comparable to that of conventional endothelial grafts. These pioneers, split into two distinct entities, are currently industrializing this therapy by injecting cells in suspension, in the USA (Aurion biotech) and in Asia (Actualeyes). In addition to injections, tissue engineered endothelial keratoplasty (TEEK) is a complementary research approach. They consist in reproducing in vitro grafts of the DMEK or DSAEK type by seeding the cultured cells on a 'corneo-compatible' support. Several have passed the preclinical stages and one is in clinical trial in Asia. Suspension cells and TEEK each have advantages and limitations that make them complementary in the management of corneal endothelial diseases.We will analyze why there is not yet an alternative process for mass production of corneal endothelial cells or clinical grade TEEK, systematically detailing the various bottlenecks identified, from the source of cells and media, to regulatory and economic aspects.


Asunto(s)
Trasplante de Córnea , Células Endoteliales , Humanos , Ingeniería de Tejidos , Ingeniería Biomédica , Bioingeniería
2.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-986692

RESUMEN

Objective To investigate the relationships between the expression levels of tumor necrosis factor receptor associated factor 4 (TRAF4) and ribosomal S6 protein kinase 4 (RSK4) protein in gastric cancer tissues and the recurrence after laparoscopic radical gastrectomy. Methods In total, 176 patients were divided into the recurrence and non-recurrence group, and the expression levels of TRAF4 and RSK4 protein in cancer and adjacent tissues and in gastric cancer tissues in the recurrence and non-recurrence group were compared. The influencing factor of recurrence and the efficacy of TRAF4 and RSK4 protein expression in predicting recurrence were analyzed. Results The positive expression rate of TRAF4 protein in gastric cancer tissues was higher than that in adjacent tissues (P < 0.05) and that in the recurrence group was higher than that in the non-recurrence group (P < 0.05). The positive expression rate of RSK4 protein in gastric cancer tissues was lower than that in adjacent tissues (P < 0.05) and that in the recurrence group was lower than that in non-recurrence group (P < 0.05). The largest tumor diameter 5 cm, poor differentiation, TNM Ⅲ stage, depth of invasion T3-T4, lymph node metastasis, absence of adjuvant chemotherapy after operation, positive expression of TRAF4 and RSK4 protein, and regular diet w influenced the post-operative recurrence (all P < 0.05). The accuracy of TRAF4 and RSK4 protein in gastric cancer tissues in combined predicting the recurrence was 83.52%. Conclusion The expression of TRAF4 protein is high, and the RSK4 protein is low in gastric cancer tissue, which are related to recurrence.

3.
Ecotoxicol Environ Saf ; 184: 109636, 2019 Nov 30.
Artículo en Inglés | MEDLINE | ID: mdl-31536849

RESUMEN

Bioremediation of chromium (Cr(Ⅵ)) contaminations has been widely reported, but the research on its removal mechanism is still scarce. Studies on Cr(Ⅵ) removal by strains affiliated to genus Pseudochobactrum revealed the Cr(Ⅵ) efficiency removal through the reduction of Cr(Ⅵ) to Cr(Ⅲ). However, the location of Cr(Ⅵ) reduction reaction and exact mechanism are still unspecified. In this work, a Gram-positive bacterial strain, Pseudochrobactrum saccharolyticum W1 (P. saccharolyticum W1) was isolated and tested to remove approximately 53.7% of Cr(Ⅵ) (initial concentration was 200 mg L-1) from the MSM medium. Analysis of SEM-EDS and TEM-EDS indicated that chromium-containing particles precipitated both on the cell surface and in the cytoplasm. Batch experiments indicated that the heat-treated bacterial cells almost had no ability to remove Cr(Ⅵ) from solution, while the resting cells could remove 62.0% of Cr(Ⅵ) at the initial concentration of 10 mg L-1. Additionally, at this concentration, 64.8% and 70.8% of Cr(Ⅵ) was reduced by cell envelope components and intracellular soluble substances after 6 h, respectively. These results suggested that the removal of Cr(Ⅵ) by P. saccharolyticum W1 was through direct reduction, which occurred on both cell envelop and cytoplasm. The results also showed that cytoplasm was the main site for Cr(Ⅵ) reduction compared to the cell envelop. Further analysis of FTIR and XPS verified that C-H, C-C, CO, C-OH and C-O-C groups of cells involved in correlation with chromium during Cr(Ⅵ) reduction. The study offered an insight into the Cr(VI) reduction mechanism of P. saccharolyticum W1.


Asunto(s)
Brucellaceae/metabolismo , Cromo/análisis , Modelos Teóricos , Biodegradación Ambiental , Brucellaceae/ultraestructura , Membrana Celular/metabolismo , Cromo/metabolismo , Citoplasma/metabolismo , Microscopía Electrónica de Rastreo , Microscopía Electrónica de Transmisión , Oxidación-Reducción
4.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-467241

RESUMEN

BACKGROUND:As the high proliferation and low apoptosis of the bone marrow in polycythemia vera patients, hematopoietic stem cels transplanted into NOD/SCID mice can differentiate into erythroid cels, but whether hematopoietic stem cels transplantation could improve the hematopoietic function of aplastic anemia mice is not yet reported. OBJECTIVE:To investigate whether transplantation of bone marrow mononuclear cels with JAK2V617F mutation from polycythemia vera patients can influence hematopoietic reconstruction in aplastic anemia mice. METHODS:Severe aplastic anemia mouse models were established by using recombinant human interferon-γplus busulfan, and then, these mouse models were randomly divided into experimental group (n=10) and control group (n=10). Bone marrow mononuclear cels isolated from polycythemia vera patients with positive JAK2V617F mutation were transplanted into the mice in the experimental group via tail vein at 5 days after drug withdrawal.The same volume of normal saline was administered to the control group. Routine peripheral blood test, morphology of bone marrow cels, bone marrow biopsy, and percentage of CD45+ cels in the peripheral blood and marrow were determined at 14 days after transplantation. RESULTS AND CONCLUSION: At 14 days after transplantation, pancytopenia occurred in the experimental group, bone marrow smears showed scattered lymphocytes and hematopoietic progenitors, and bone marrow biopsy presented that hematopoietic tissues were reduced and a smal amount of granulocyte cels and erythroblasts could be seen, but megakaryocytes were rare. In contrast to the control group, there was no improvement in the hematopoietic function of mice in the experimental group. CD45+ cels were detectable in the peripheral blood and bone marrow in the experimental group, but not in the control group; and a higher percentage of CD45+ cels was measured in the bone marrow than in the peripheral blood of experimental group mice. Experimental findings indicate that bone marrow mononuclear cels from polycythemia vera patients with positive JAK2V617F mutation can be engrafted into aplastic anemia mice, but cannot improve the hematopoietic function of mice.

5.
Chinese Journal of Rheumatology ; (12): 697-699, 2014.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-460056

RESUMEN

Objective To evaluate the significance of platelet activation and the expression of inter-leukin (IL)-1β in patients with RA. Methods The activation of platelets and the expression of IL-1β in pla-telets in 50 RA patients(22 high-active, 28 mediate/low active ) and 30 normal controls were determined us-ing flow cytometry. Meanwhile, inflammatory indicators such as erythrocyte sedimentation(ESR), C-reactive protein (CRP) and DAS28 were also recorded. T test and correlation analysis were performed. Results The platelet activation in RA group(19.2±4.8) was higher than the control group(9.0±2.9)(t=10.5, P=0.001). The expression of IL-1β in platelets in RA group(41±11) was higher than control group(21±8)(t=9.01, P =0.000) .The platelet activation in high-active RA group(22 ±4) was higher than mediate/low active RA group(17 ±4)(t =3.96,P =0.001). The expression of IL-1β in platelets in high-active RA group(45 ±10) was higher than mediate/low active RA group (38 ±10)(t =2.329,P =0.024). The expression of IL-1β in platelets in RA group was positively correlated with the level of ESR、CRP and DAS28 (r value and P value were 0.576, 0.578, 0.618 and 0.000, 0.000, 0.000 respectively). Conclusion The platelets of patients with RA are activated and may suggest that IL-1β, which may associate with disease activity. Our research suggest that platelet may play a role in the inflammatory process of RA by secreting IL-1β.

6.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-456465

RESUMEN

BACKGROUND:It is important to establish an ideal mouse model of severe aplastic anemia for investigating the mechanism and finding new therapies for aplastic anemia. OBJECTIVE:To establish a severe aplastic anemia mouse model by using recombinant human interferon-γand busulfan. METHODS:Sixty healthy Kunming female mice were randomly divided into two groups:model group (n=50) and control group (n=10). The model group was given recombinant human interferon-γat a dose of 1×104 U/d by intraperitoneal injection and busulfan at a dose of 18 mg/(kg·d) through stomach feeding for 7 days. The same volume of physiological saline was given to control group. Multi-parameters, including general condition, body weight, blood cellcount, morphology and biopsy of bone marrow were analyzed in two groups. RESULTS AND CONCLUSION:At day 7 after treatment, the weight, white blood cellcount, hemoglobin, blood platelet, reticulocyte count in model group were significantly lower than control group (P<0.05). Bone marrow smears and biopsy of model group showed marked reduction of bone marrow proliferation and increases of percentages of non-hematopoietic cellclusters and adipose tissue. The oil drop and fat vacuole were apparently seen in the model group. Severe aplastic anemia mouse model can be established by using recombinant human interferon-γand busulfan successful y, which is economic, stable and easy to operate.

7.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-386589

RESUMEN

Objective To evaluate the benefits of perioperative fast-track surgery (FTS) program on clinical outcome in patients with gastric cancer. Methods Totally, 82 patients were randomly allocated into FTS group (n = 41; received perioperative FTS program) and control group (n = 41; received a conventional therapy). The postoperative first defecation time, postoperative hospital stay, hospitalization expenditure, and postoperative complications were compared between the two groups. Results The postoperative first defecation time and postoperative hospital stay were (45.58 ± 26.91 ) h and (9.4 ± 3. 3 ) d in FT3 group and (58.01 ± 23.5 ) h and ( 12. 4 ±3.6 )d in control group (P = 0. 0287 and P = 0. 0002, respectively). Hospitalization expenditure was significantly lower in FTS group than that in control group [(2. 96 ± 0.44 ) yuan vs. ( 3.46 ± 0. 34 ) × 104 yuan, P < 0. 0001 ).The complication was not significantly different between the two groups (7.3% vs. 17.1% , P =0. 232). Conclusion Perioperative FTS program can accelerate postoperative rehabilitation, shorten hospital stay, and decrease medical costs in patients with gastric cancer.

8.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-407448

RESUMEN

A cidithiobacillus ferrooxidans is a chemolithotrophic microorganism capable of using ferrous ions and sulphides as energy sources. This microorganism has an important role in the bioleaching of minerals. During this process, the bacteria are normally subjected to several stressing conditions, such as temperature changes, lack of nutrients or pH changes, which may affect the efficiency of the bacterial action. SELDI is a recent technology that allows for high-throughput proteomics studies. The Protein Chip SELDI technology was used to generate comparative protein profiles of A c idithiobacillus ferrooxidans grown under phosphate starvation or normal condition additionally adding Fe2+ as energy resource. There were 13 significantly differential expressed protein's peaks found by using SELDI Protein Chip technologies, which made a solid foundation for further isolation these low molecular proteins by adopting technologies such as HPLC etc.

9.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-564668

RESUMEN

Objective To study the effctiveness and safety of arsenic trioxide(As2O3)combined with Homoharringtoninum in the chronic myelocytic leukmia-chonic phase(CML-CP).Methods Seven patients were treated with As2O3 10mg per day for 2~3 week and with Homoharringtoninum 3~4mg per day for 1~2.Results All patients were clinic remission,of which there were 4 complete remission who were all initial therapy,and 3 partial remission,2 of who were initial therapy and 1 was resume threapy.4 patients of CR were treated with second strengthen therapy and continued hematologic CR.The main side effects were grade 3 hematologic toxicity and light liver damage,and no significant nausea,emesis,diarrhea or mucositis.Conclusion As2O3 combined with Homoharringtonium in the CML-CP is a safe and effctive regimen.

10.
Herald of Medicine ; (12): 107-2001.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-564865

RESUMEN

Objective:To explore the effective drug and the best way of administration of the drug in the relief of moderate or severe cancer pain,so as to attain the best effect.Methods:30 patients with moderate or later period cancer orally take 30 mg Morphine tablet every 12 hours. The initial dose was 60 mg,and then it was adjusted according to the effect till the most appropriate dose was reached.Results:After taking Morphine tablet,the rate of complete relief and moderate relief of moderate or severe cancer pain were 70%(21/30),26.7%(8/30),respectively. The total effective rate was 96.7%.Conclusion:Effect of Morphine tablet for cancer pain treatment was sure and reliable,the administration of 30 mg Morphine tablet every 12 hours was safe and effective.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...